Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-8.54%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.39% | 34.59% | 10.14% | 15.99% | -76.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.39% | 34.59% | 10.14% | 15.99% | -76.55% |
| Cost of Revenue | 12.33% | 71.43% | 4.14% | -1.82% | -46.64% |
| Gross Profit | 1.88% | 24.62% | 11.58% | 20.02% | -83.56% |
| SG&A Expenses | -10.07% | -43.81% | -17.56% | -0.93% | -3.95% |
| Depreciation & Amortization | -66.37% | -72.01% | -73.42% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 955.60% | -23.33% | -14.45% | 9.50% | -91.97% |
| Operating Income | -1,497.25% | 433.50% | 59.75% | 9.94% | 111.50% |
| Income Before Tax | -671.76% | 191.77% | 33.71% | -230.76% | 119.88% |
| Income Tax Expenses | -- | -- | 50.00% | -12.50% | -- |
| Earnings from Continuing Operations | -671.65% | 191.80% | 33.66% | -232.05% | 119.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -671.65% | 191.80% | 33.66% | -232.05% | 119.88% |
| EBIT | -1,497.25% | 433.50% | 59.75% | 9.94% | 111.50% |
| EBITDA | -907.55% | 605.74% | 57.90% | 17.51% | 119.63% |
| EPS Basic | -608.64% | 166.32% | 43.09% | -178.97% | 105.20% |
| Normalized Basic EPS | -601.96% | 166.48% | -27.08% | -175.59% | 104.29% |
| EPS Diluted | -20,700.00% | 100.69% | 43.09% | -2,600.00% | 100.13% |
| Normalized Diluted EPS | -25,700.00% | 100.56% | -27.08% | -2,020.00% | 100.08% |
| Average Basic Shares Outstanding | 12.76% | 37.96% | 23.97% | 73.25% | 278.80% |
| Average Diluted Shares Outstanding | -97.84% | 23,852.46% | 23.97% | -92.83% | 19,631.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |